Enhance LNP Characterization & Analytical Methods Across Pipeline Development to Deepen Insight into LNP Structure, Ensuring Stability & Integrity, Bolstering Confidence in Regulatory Submissions

Turbocharged by increased LNP pipeline development and technological advancements with SPARTA biodiscovery raising $4.3m for their characterization technology, UPENN engineers developing CAR-T therapies, and Genevant securing a $114m deal with Tome. As the industry places a greater emphasis on later-phase assets, understanding the intricacies of LNPs and investing in analytical assays are becoming essential for ensuring market confidence.

Join a community of 60+ analytical, potency, and characterization experts at the 2nd Characterization & Analytical Development Summit this November to enable you to:

  • Evaluate different characterization techniques for early-stage development to select the most robust methods: fluorescence, chromatography, imaging, and cryo-EM
  • Conduct biophysical characterization to comprehend LNP in vivo and in vitro behavior
  • Analyze complex LNP drug products with targeting moieties and multiple payloads across oligonucleotides, CRISPR-Cas9, RNAs, and beyond
  • Develop potency assays for safety and quality assessments, employing gold standard techniques and validated assays
  • Explore robustly tested critical quality attributes and release criteria for confidence in pipeline development and regulatory submission

As the only summit dedicated to LNP drug product characterization and analytical development, join us this November to unite the industry and advance LNP analytics, deriving practical applications to drive quality, efficacious LNPs.

Our Industry-Leading Speakers Include:

Industry & Academic Expert Presenters
Jam-Packed Days of Exclusive Content
Deep-Dive & Collaborative Workshops

Companies in Our Event Community:

2024 Partners:

What Previous Attendees of the LNP Series Had To Say:

"I really value the ability to communicate with scientists in the field; seeing emerging techniques for analytical characterization and development." - Analytical Research Scientist

Acuitas Therapeutics, 2nd LNP Characterization & Analytical Development
NIST, 2nd LNP Characterization & Analytical Development

"Very relevant presentations and interesting mix of speakers from many of the key players in LNP/mRNA analytics. Very good audience which led to many opportunities for discussions and follow up." - Physicist

"I enjoyed seeing the most advanced and relevant information, as well as communication and networking with the best professionals in the area of LNP characterization and analytical development." - Associate Director

Nitto Denko, 2nd LNP Characterization & Analytical Development
Moderna, 2nd LNP Characterization & Analytical Development

"I enjoyed all of the presentations. The conference was very well organized and ran smoothly." - Principal Research Associate

"Well attended, engaged participants, good speaker lineup, current and future challenges were discussed, ample time for networking. What stood out for me was the energy and interest from all parties." - Director